Sanofi (SNY) Shares Bought by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. boosted its position in shares of Sanofi (NYSE:SNY) by 14.3% during the second quarter, Holdings Channel reports. The firm owned 255,713 shares of the company’s stock after buying an additional 31,980 shares during the period. Tocqueville Asset Management L.P.’s holdings in Sanofi were worth $10,702,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its stake in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock worth $146,000 after buying an additional 490 shares during the period. JFS Wealth Advisors LLC boosted its stake in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the period. BlackRock Institutional Trust Company N.A. purchased a new stake in Sanofi during the first quarter worth about $175,000. Rehmann Capital Advisory Group boosted its stake in Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the period. Finally, Cypress Wealth Advisors LLC purchased a new stake in Sanofi during the first quarter worth about $247,000. Institutional investors own 9.37% of the company’s stock.
Sanofi (NYSE:SNY) traded down 1.09% during mid-day trading on Monday, hitting $37.34. 1,239,387 shares of the stock traded hands. The firm’s 50-day moving average price is $38.65 and its 200-day moving average price is $40.40. The firm has a market cap of $96.11 billion, a P/E ratio of 20.84 and a beta of 0.98. Sanofi has a 52 week low of $37.20 and a 52 week high of $51.88.
A number of research firms have issued reports on SNY. Zacks Investment Research upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Monday, July 25th. Leerink Swann reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, September 26th. Citigroup Inc. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. Jefferies Group reaffirmed a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Sanofi in a research report on Thursday, September 15th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $60.50.
Sanofi Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.